Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Politics, Policy & Law: Shorter and fatter

How 21st Century Cures draft boosts NIH budget, addresses FDA concerns

By Steve Usdin, Washington Editor

The House Energy & Commerce Committee's 21st Century Cures draft legislation got 200 pages shorter and $10 billion more expensive last week as Republicans dropped controversial provisions and added NIH funding to gain support from Democrats.

The second iteration of the legislative discussion draft remains very much a work in progress with large portions bracketed, meaning the language is tentative, and with several placeholders indicating areas where there isn't sufficient agreement to propose even bracketed text.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.